Hello – Today, we’re inviting you to take a free look at MarketBeat’s proprietary, up-to-the-minute list of 20 stocks that Wall Street’s top-rated analysts hate. These aren’t mild downgrades or lukewarm opinions.
These are true Strong Sell stocks. Some of them may look fine on the surface. A few even have what appear to be solid fundamentals. But when analysts issue a rare Sell rating, it’s usually because something beneath the surface is deeply wrong. Sell-side analysts may not nail every Buy call… but when they raise red flags, they’re almost always worth listening to. If any of these stocks are lurking around in your portfolio, you may seriously want to consider dumping them.
Click here to see the list now. Stay one step ahead, Matthew Paulson
Founder & CEO, MarketBeat
P.S. Access to 20 Stocks to Sell Now is completely free. Don’t miss your chance to review these timely, high-conviction warnings before the market reacts.
Exclusive Content
3 Penny Stocks Under $5 Backed by Real Revenue GrowthReported by Chris Markoch. Article Published: 6/20/2026. 
Key Points
- These three penny stocks generate real revenue, separating them from many speculative story stocks.
- Ur-Energy, Grab Holdings, and Aclaris Therapeutics each have catalysts that could support future growth and profitability.
- Analyst price targets suggest meaningful upside potential despite the risks that come with investing in stocks under $5.
- Special Report: Everyone wanted SpaceX. Smart money wants this.
Investing in penny stocks requires a great deal of conviction. Many companies in this space are essentially “story stocks.” That means they’re not profitable, and many don’t even generate revenue. Investors don't evaluate these companies using metrics such as price-to-earnings ratios or free cash flow. Instead, they invest based on the story behind the stock. At its worst, this can create conditions similar to the meme stock frenzy of 2020 and 2021. Many stocks debuted with little more than a story and soared to unsustainable levels, only to crash back down when reality set in. Many of those companies are now back to trading as penny stocks, and investors are wisely evaluating them with more scrutiny.
In February 2016, Louis Navellier recommended Nvidia at $2.51 split-adjusted - before a 44,000% gain. He also called Apple before a 36,000% rise and Microsoft before a 60,800% climb.
Now Navellier says he's seeing the same data pattern in a little-known company tied to a government AI project called Golden Dawn - a system he believes could trigger a $100 trillion reset of AI markets. He's revealing the name and ticker for free. Get the full details and the ticker in Navellier's free presentation
But not all penny stocks are bad investments. Some are simply early in their growth cycle. While they may not be profitable yet, they are generating revenue and have catalysts that could put them on a path to profitability. That’s the case with three stocks trading below $5 as of this writing, and analysts believe each could be headed much higher. Ur-Energy Could Benefit From the Global Nuclear RevivalUr-Energy (NYSEAMERICAN: URG) is a small-cap company that explores, develops and produces uranium. The company’s core expertise centers on in situ recovery (ISR) mining techniques, which involve extracting uranium from sandstone formations through a low-environmental-impact process. The company’s flagship ISR operation is its Lost Creek project in Wyoming. However, analysts expect the strongest growth from the company’s Shirley Basin project, which has been idle since 1992. That is expected to have a more meaningful impact on Ur-Energy's balance sheet in the second half of 2026, when the company is also expected to turn a profit on a non-GAAP basis. Nuclear energy is experiencing a revival. After decades of falling out of favor, the International Atomic Energy Agency (IAEA) projects global nuclear capacity could double by 2050, with significant near-term growth expected from 2026 through 2030. And this isn’t being driven by the United States alone. China, India and Russia are also expanding their nuclear power infrastructure. That supply-demand setup for uranium prices makes a low-cost miner such as Ur-Energy a potentially lucrative investment. The Ur-Energy analyst forecasts on MarketBeat show six analysts offering a rating with a consensus price target of $2.57. Grab Holdings Offers Growth Potential at a Discounted PriceGrab Holdings (NASDAQ: GRAB) may be the best-known name on this list of penny stocks. The company operates a consumer-facing “super app” across Southeast Asia. The app offers services including ride-hailing, food and package delivery, and digital payments. The latter is part of Grab Financial Group, which could be a significant driver of the company's growth. Revenue growth isn’t the problem, and it should be noted that Grab has been profitable. But GRAB has been a poor investment almost since its debut in 2021. Over the last 12 months, the stock is down more than 20% and is down about 30% in 2026. However, that seems like a case of the story getting ahead of the stock. The 10 analysts who have offered a price target for GRAB suggest there could be significant upside ahead. Insider selling of penny stocks is often amplified, especially when, as with GRAB, there are no corresponding share purchases. But the selling in May 2026 all indicated that it was part of a Rule 10b5-1(c) plan. These are structured sales that are scheduled months in advance, often to help manage an event like a tax deadline. Aclaris Therapeutics Combines Revenue With Biotech UpsideBiotechnology and penny stocks go together like peanut butter and jelly. However, they aren’t always so appetizing for investors. That’s because a biotechnology stock that’s a penny stock usually means the company is still in the clinical stage, which means it doesn’t have a drug or therapy on the market. That’s the case for Aclaris Therapeutics (NASDAQ: ACRS). In fact, the company has no assets beyond Phase 2 trials that are under its own umbrella. Its lead candidate, bosakitug, is licensed from Biosion, and a Chinese partner is running additional trials of the drug overseas. The company also receives a nominal amount of licensing revenue from agreements with Eli Lilly (NYSE: LLY) and Sun Pharma. That’s not enough reason to consider ACRS. A better reason is the analysts' outlook. In this case, eight analysts have issued price targets, and the consensus price target is more than 150% above the stock price as of this writing. ACRS is up more than 200% over the last 12 months. That may have more to do with speculation, so investors looking to get involved may want to wait for more data on the company’s pipeline. |
No comments:
Post a Comment